Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q2 FY22 results · Jul–Sep 2021
Torrent Pharmaceuticals reported revenue from operations of ₹2,137.00 crore (up 5.9% from Q2 FY21) and net profit of ₹316.00 crore (up 1.9% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,137.00 | 2,017.00 | +5.9% | 2,134.00 | +0.1% |
| Other income | 51.00 | 6.00 | +750.0% | 40.00 | +27.5% |
| Total income | 2,188.00 | 2,023.00 | +8.2% | 2,174.00 | +0.6% |
| Profit before tax | 472.00 | 384.00 | +22.9% | 484.00 | −2.5% |
| Net profit for the period | 316.00 | 310.00 | +1.9% | 330.00 | −4.2% |
| EPS, basic (₹) | 18.63 | 18.32 | +1.7% | 19.53 | −4.6% |
| Net margin (%) | 14.8 | 15.4 | 15.5 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,799.00 | 1,640.00 | +9.7% | 1,695.00 | +6.1% |
| Other income | 54.00 | 9.00 | +500.0% | 50.00 | +8.0% |
| Total income | 1,853.00 | 1,649.00 | +12.4% | 1,745.00 | +6.2% |
| Profit before tax | 454.00 | 356.00 | +27.5% | 412.00 | +10.2% |
| Net profit for the period | 326.00 | 283.00 | +15.2% | 274.00 | +19.0% |
| EPS, basic (₹) | 19.24 | 16.68 | +15.3% | 16.21 | +18.7% |
| Net margin (%) | 18.1 | 17.3 | 16.2 |
Consolidated
- Filed with BSE
- 27 Oct 2021, 12:20 IST
- Board meeting
- 26 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Oct 2021, 12:20 IST
- Board meeting
- 26 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Audited
- Source
- XBRL filing on BSE